Vontobel Asset Management Inc. lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.4% during the 4th quarter, Holdings Channel reports. The firm owned 3,121,360 shares of the healthcare product maker’s stock after selling 13,301 shares during the quarter. Abbott Laboratories accounts for about 1.3% of Vontobel Asset Management Inc.’s investment portfolio, making the stock its 27th largest holding. Vontobel Asset Management Inc.’s holdings in Abbott Laboratories were worth $184,175,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ABT. Rowland & Co. Investment Counsel ADV bought a new stake in Abbott Laboratories in the 4th quarter worth $102,000. Heritage Trust Co lifted its position in shares of Abbott Laboratories by 10.1% in the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after purchasing an additional 200 shares during the period. Tributary Capital Management LLC purchased a new stake in shares of Abbott Laboratories in the 3rd quarter worth about $106,000. Thompson Davis & CO. Inc. lifted its position in shares of Abbott Laboratories by 17.7% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after purchasing an additional 370 shares during the period. Finally, Motco lifted its position in shares of Abbott Laboratories by 213.7% in the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock worth $140,000 after purchasing an additional 1,962 shares during the period. 70.61% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories (NYSE:ABT) opened at $57.41 on Tuesday. The stock has a market cap of $99,510.16, a PE ratio of 220.82, a P/E/G ratio of 1.72 and a beta of 1.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a 12-month low of $42.31 and a 12-month high of $64.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The business had revenue of $7.59 billion during the quarter, compared to analyst estimates of $7.38 billion. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.80%. Abbott Laboratories’s revenue was up 42.3% compared to the same quarter last year. During the same period last year, the business earned $0.65 EPS. equities analysts anticipate that Abbott Laboratories will post 2.86 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.28 dividend. The ex-dividend date is Thursday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.95%. Abbott Laboratories’s payout ratio is currently 430.79%.

Several equities research analysts have recently commented on the stock. Barclays raised their target price on shares of Abbott Laboratories from $66.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, January 25th. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price on shares of Abbott Laboratories in a research report on Thursday, January 25th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $67.00 target price on shares of Abbott Laboratories in a research report on Thursday, January 25th. Leerink Swann reaffirmed a “market perform” rating and issued a $68.00 target price (up from $60.00) on shares of Abbott Laboratories in a research report on Thursday, January 25th. Finally, Citigroup raised their target price on shares of Abbott Laboratories from $59.00 to $64.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $65.47.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares in the company, valued at $572,900.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Stephen R. Fussell sold 13,313 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total transaction of $836,588.92. Following the completion of the sale, the executive vice president now owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The disclosure for this sale can be found here. Insiders sold 374,458 shares of company stock valued at $20,752,706 over the last quarter. Company insiders own 0.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/vontobel-asset-management-inc-sells-13301-shares-of-abbott-laboratories-abt/1863608.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.